316 related articles for article (PubMed ID: 22820140)
1. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
2. Protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinase 1 and 2 in papillary thyroid carcinomas.
Maeta H; Ohgi S; Terada T
Virchows Arch; 2001 Feb; 438(2):121-8. PubMed ID: 11253113
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of matrix metalloproteinase-2: a diagnostic marker but not prognostic marker of papillary thyroid carcinoma.
Korem S; Kraiem Z; Shiloni E; Yehezkel O; Sadeh O; Resnick MB
Isr Med Assoc J; 2002 Apr; 4(4):247-51. PubMed ID: 12001695
[TBL] [Abstract][Full Text] [Related]
4. Expression of the membrane mucins MUC4 and MUC15, potential markers of malignancy and prognosis, in papillary thyroid carcinoma.
Nam KH; Noh TW; Chung SH; Lee SH; Lee MK; Hong SW; Chung WY; Lee EJ; Park CS
Thyroid; 2011 Jul; 21(7):745-50. PubMed ID: 21615302
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
Wu G; Zhou Y; Li T; Guo J; Zhou Z
J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
[TBL] [Abstract][Full Text] [Related]
6. Matrix metalloproteinase (MMP) expression by differentiated thyroid carcinoma of children and adolescents.
Patel A; Straight AM; Mann H; Duffy E; Fenton C; Dinauer C; Tuttle RM; Francis GL
J Endocrinol Invest; 2002 May; 25(5):403-8. PubMed ID: 12035934
[TBL] [Abstract][Full Text] [Related]
7. [Expression of matrix metalloproteinases 2 and 9 and their tissue inhibitors 1 and 2 in papillary thyroid cancer: an association with the clinical, morphological and ultrastructural characteristics of a tumor].
Delektorskaia VV; Smirnova EA; Ponomareva MV; Pavlova TV; Pavlov IA
Arkh Patol; 2010; 72(4):3-6. PubMed ID: 21086628
[TBL] [Abstract][Full Text] [Related]
8. Urokinase receptor, MMP-1 and MMP-9 are markers to differentiate prognosis, adenoma and carcinoma in thyroid malignancies.
Buergy D; Weber T; Maurer GD; Mudduluru G; Medved F; Leupold JH; Brauckhoff M; Post S; Dralle H; Allgayer H
Int J Cancer; 2009 Aug; 125(4):894-901. PubMed ID: 19480010
[TBL] [Abstract][Full Text] [Related]
9. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
10. Matrix metalloproteinase-9 and the Cu/Zn ratio as ancillary diagnostic tools in distinguishing between the classical and follicular variants of papillary thyroid carcinoma.
Dragutinović VV; Tatić SB; Nikolić-Mandić S; Savin S; Cvejić D; Dunđerović D; Gajić M; Paunović I
Biol Trace Elem Res; 2012 Oct; 149(1):29-33. PubMed ID: 22528774
[TBL] [Abstract][Full Text] [Related]
11. Role of matrix metalloproteinases and their inhibitors in the development of cervical metastases in papillary thyroid cancer.
Bumber B; Marjanovic Kavanagh M; Jakovcevic A; Sincic N; Prstacic R; Prgomet D
Clin Otolaryngol; 2020 Jan; 45(1):55-62. PubMed ID: 31646745
[TBL] [Abstract][Full Text] [Related]
12. Human thyroid carcinoma cell lines and normal thyrocytes: expression and regulation of matrix metalloproteinase-1 and tissue matrix metalloproteinase inhibitor-1 messenger-RNA and protein.
Aust G; Hofmann A; Laue S; Rost A; Köhler T; Scherbaum WA
Thyroid; 1997 Oct; 7(5):713-24. PubMed ID: 9349574
[TBL] [Abstract][Full Text] [Related]
13. [Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid].
Wang T; Jiang CX; Li Y; Liu X
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):824-8. PubMed ID: 20193458
[TBL] [Abstract][Full Text] [Related]
14. Activation of the ROCK1/MMP-9 pathway is associated with the invasion and poor prognosis in papillary thyroid carcinoma.
Luo D; Chen H; Li X; Lu P; Long M; Peng X; Lin S; Tan L; Zhu Y; Ouyang N; Li H
Int J Oncol; 2017 Oct; 51(4):1209-1218. PubMed ID: 28848996
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
16. The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Fanaei SA; Hedayati M; Azizi F
BMC Cancer; 2018 Dec; 18(1):1199. PubMed ID: 30509240
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinases and their specific inhibitors in normal and different human thyroid tumor cell lines.
Baldini E; Toller M; Graziano FM; Russo FP; Pepe M; Biordi L; Marchioni E; Curcio F; Ulisse S; Ambesi-Impiombato FS; D'Armiento M
Thyroid; 2004 Nov; 14(11):881-8. PubMed ID: 15671765
[TBL] [Abstract][Full Text] [Related]
18. Expression of MMP-13 is associated with invasion and metastasis of papillary thyroid carcinoma.
Wang JR; Li XH; Gao XJ; An SC; Liu H; Liang J; Zhang K; Liu Z; Wang J; Chen Z; Sun W
Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):427-35. PubMed ID: 23467939
[TBL] [Abstract][Full Text] [Related]
19. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.
Wang N; Jiang R; Yang JY; Tang C; Yang L; Xu M; Jiang QF; Liu ZM
J Mol Histol; 2014 Aug; 45(4):391-9. PubMed ID: 24276590
[TBL] [Abstract][Full Text] [Related]
20. mRNA levels of membrane-type 1 matrix metalloproteinase (MT1-MMP), MMP-2, and MMP-9 and of their inhibitors TIMP-2 and TIMP-3 in normal thyrocytes and thyroid carcinoma cell lines.
Hofmann A; Laue S; Rost AK; Scherbaum WA; Aust G
Thyroid; 1998 Mar; 8(3):203-14. PubMed ID: 9545106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
